AYAL Capital Advisors Ltd Buys 100,000 Shares of Surgery Partners, Inc. $SGRY

AYAL Capital Advisors Ltd raised its holdings in shares of Surgery Partners, Inc. (NASDAQ:SGRY) by 80.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 225,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Surgery Partners accounts for about 1.2% of AYAL Capital Advisors Ltd’s portfolio, making the stock its 27th largest position. AYAL Capital Advisors Ltd owned 0.17% of Surgery Partners worth $3,476,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Jones Financial Companies Lllp grew its position in Surgery Partners by 313.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after purchasing an additional 930 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Surgery Partners by 45,640.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock valued at $49,000 after purchasing an additional 2,282 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock valued at $58,000 after purchasing an additional 1,519 shares during the period. Aquatic Capital Management LLC acquired a new position in shares of Surgery Partners in the 3rd quarter valued at $121,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Surgery Partners by 68.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,313 shares of the company’s stock valued at $207,000 after purchasing an additional 3,794 shares during the period.

Surgery Partners Trading Down 6.0%

NASDAQ:SGRY opened at $14.23 on Thursday. The company has a market capitalization of $1.86 billion, a PE ratio of -23.72, a price-to-earnings-growth ratio of 4.53 and a beta of 1.96. The stock has a fifty day simple moving average of $13.90 and a 200-day simple moving average of $14.47. Surgery Partners, Inc. has a 52-week low of $11.41 and a 52-week high of $24.10. The company has a quick ratio of 1.69, a current ratio of 1.86 and a debt-to-equity ratio of 1.17.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.12. The firm had revenue of $810.90 million during the quarter, compared to analysts’ expectations of $797.69 million. Surgery Partners had a positive return on equity of 1.04% and a negative net margin of 2.28%.The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.04 EPS. On average, equities research analysts expect that Surgery Partners, Inc. will post 0.25 earnings per share for the current fiscal year.

Surgery Partners announced that its Board of Directors has authorized a share buyback plan on Thursday, February 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 9.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts recently commented on SGRY shares. Benchmark reissued a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. US Capital Advisors set a $21.00 price objective on shares of Surgery Partners in a report on Wednesday, March 11th. UBS Group reaffirmed a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 11th. Barclays decreased their target price on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada reduced their target price on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.18.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.